FDA expected to weigh in on Avandia risk

With the future of GlaxoSmithKline's Avandia diabetes drug hanging in the balance, the Food and Drug Administration was expected to release a key staff report on suspected health risks Friday that likely will figure prominently in deciding whether the drug should remain on the market.